- Home
- HLIO vs MNKD Comparison
HLIO vs MNKD Comparison
Compare HLIO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLIO
- MNKD
- Stock Information
- Founded
- HLIO 1970
- MNKD 1991
- Country
- HLIO United States
- MNKD United States
- Employees
- HLIO N/A
- MNKD N/A
- Industry
- HLIO Metal Fabrications
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- HLIO Industrials
- MNKD Health Care
- Exchange
- HLIO Nasdaq
- MNKD Nasdaq
- Market Cap
- HLIO 1.7B
- MNKD 1.8B
- IPO Year
- HLIO N/A
- MNKD 2004
- Fundamental
- Price
- HLIO $50.44
- MNKD $6.22
- Analyst Decision
- HLIO Buy
- MNKD Strong Buy
- Analyst Count
- HLIO 2
- MNKD 5
- Target Price
- HLIO $63.00
- MNKD $8.40
- AVG Volume (30 Days)
- HLIO 147.6K
- MNKD 2.8M
- Earning Date
- HLIO 11-05-2024
- MNKD 11-07-2024
- Dividend Yield
- HLIO 0.71%
- MNKD N/A
- EPS Growth
- HLIO N/A
- MNKD N/A
- EPS
- HLIO 1.13
- MNKD 0.08
- Revenue
- HLIO $819,800,000.00
- MNKD $267,200,000.00
- Revenue This Year
- HLIO N/A
- MNKD $45.36
- Revenue Next Year
- HLIO $1.58
- MNKD $16.99
- P/E Ratio
- HLIO $44.76
- MNKD $74.80
- Revenue Growth
- HLIO N/A
- MNKD 51.35
- 52 Week Low
- HLIO $39.08
- MNKD $3.17
- 52 Week High
- HLIO $57.29
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- HLIO 43.00
- MNKD 38.90
- Support Level
- HLIO $50.91
- MNKD $5.81
- Resistance Level
- HLIO $54.35
- MNKD $6.77
- Average True Range (ATR)
- HLIO 1.47
- MNKD 0.25
- MACD
- HLIO -0.40
- MNKD -0.07
- Stochastic Oscillator
- HLIO 6.34
- MNKD 36.44
About HLIO Helios Technologies Inc.
Helios Technologies Inc is a industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic cartridge valves, hydraulic quick release couplings as well as engineers complete hydraulic systems. The Electronics segment designs and manufactures customized electronic controls systems and displays for a variety of end markets including industrial and mobile, recreational and health and wellness.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.